Does the pentapeptide PLNPK inhibit systemic lupus erythematosus-associated renal damage?
Our results demonstrate that PLNPK can suppress T cell function and reduce the production of autoantibodies, and may be a feasible and effective therapy in the SLE model.
S100A4 promotes liver fibrosis by activating HSCs, which may represent a potential target for anti-fibrotic therapies.